On Thursday, Shares of Alcatel Lucent SA (ADR) (NYSE:ALU), lost -0.50% to $3.95.
Bell Labs, the research arm of Alcatel-Lucent (Euronext Paris and NYSE: ALU) has made a breakthrough in its ambition to shatter the capacity limits of optical networks as they strive to meet the explosion in traffic predictable from 5G and the Internet of Things.
According to a study by Bell Labs, telecommunications operators and enterprises are witnessing rapid network data traffic growth at cumulative annual rates of up to 100 percent. With the promise of 5G wireless technology on the horizon, Bell Labs estimates that, within about a decade there will be an acute need for commercial optical transport systems capable of handling Petabit-per-second capacities.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), inclined 0.31% to $12.85, during its last trading session.
ZIOPHARM Oncology, declared that the Company is presenting initial results from an ongoing Phase 1 dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant glioma. The presentation, titled “Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Treatment of Glioma,” will be delivered at 5:15 pm CT, Saturday, November 21, 2015 at the 20th Annual Society for Neuro-Oncology (SNO) Annual Scientific Meeting in San Antonio, Texas. Ad-RTS-hIL-12 + the oral activator veledimex is a novel viral gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T-cell immune response.
“Immunotherapy is an attractive approach for the treatment of glioma, an aggressive cancer with few treatment options,” said Nino Chiocca, MD, PhD, Harvey W. Cushing Professor of Neurosurgery, Department of Surgery, Harvard Medical School, Surgical Director, Center for Neuro-oncology, Dana-Farber Cancer Institute, Chairman, Neurosurgery, Brigham And Women’s Hospital and Co-Director, Institute for the Neurosciences, Brigham And Women’s Hospital. “IL-12 is among the most potent anti-cancer immune cytokines, yet carries equally noteworthy potential for immune-mediated toxicities. The ability to turn IL-12 expression on and off using an orally activated gene switch, particularly in the brain’s immune privileged environment, is a tremendous advancement in the potential of this therapeutic approach. We look forward to enrolling additional patients and follow up from this study to evaluate Ad-RTS-IL-12’s potential in this challenging, rapidly advancing and lethal disease.”
The ongoing multi-center Phase 1 trial of Ad-RTS-hIL-12 + veledimex examines a gene therapy strategy for recurrent high grade gliomas, with the aim of generating a localized anti-tumor immune response. The primary objective of the study is to determine the safety and tolerability of a single intra-tumoral Ad-RTS-hIL-12 injection activated upon dosing with oral veledimex. Secondary objectives are to determine the Ad-RTS-hIL-12 + veledimex maximum tolerated dose, the immune responses elicited by Ad-RTS-hIL-12 + veledimex, and assessment of biologic response. The study is predictable to enroll up to 72 subjects.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
Finally, Shares of JetBlue Airways Corporation (NASDAQ:JBLU), ended its last trade with 0.79% gain, and closed at $25.67.
JetBlue Airways, declares the first JetBlue LIVE concert experience in San Juan. In partnership with MasterCard and Banco Santander, JetBlue is providing an exclusive pop-up performance featuring popular Puerto Rican singer/songwriter and actor — Pedro Capo. This concert, sponsored by the Santander JetBlue MasterCard, will take place on Thursday, December 3, 2015 at 4:30 p.m. at Luis Muñoz Marín International Airport (SJU) in San Juan, one of JetBlue’s six focus cities. This concert will be available exclusively to lucky travelers, select Santander JetBlue MasterCard card members and contest winners selected by Pedro Capo.
JetBlue LIVE is JetBlue’s signature live music platform and comprises the airline’s award-winning Live From T5 Concert Series. This will be the third JetBlue LIVE concert held outside of T5 at JFK Airport in New York. This also marks the first show in Puerto Rico. Past JetBlue LIVE concerts have featured Lady Antebellum and Gary Clark, Jr.
A modern-day renaissance man, Pedro Capo has starred in major motion pictures, performed in hit theatrical productions, wrote widely-acclaimed songs for award-winning international superstars counting Ricky Martin and Ednita Nazario and boasts seven #1 radio singles in Puerto Rico. This concert will serve as a homecoming for Pedro. Born in San Juan, Puerto Rico, he lives a life of free-thinking and inspiration. He’s the grandson of famous Puerto Rican singer Bobby Capo and son of the well-remembered singer and founder of the Salsa nueva trova, also named Bobby Capo. Pedro is the third in a family of tradition that left its stamp on Latin music and Puerto Rican culture.
JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 13 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 EMBRAER 190 aircrafts.